The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C
- 1 November 2016
- journal article
- clinical trial
- Published by Wiley in Transplant Infectious Disease
- Vol. 18 (6) , 896-903
Abstract
Background: The new directly acting antivirals (DAAs) enable all‐oral interferon‐free treatment of chronic hepatitis C virus (HCV) infection. We here investigated the effect ofDAAs on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.Methods: Twenty‐one patients with elevated liver enzymes or advanced fibrosis/compensated cirrhosis caused by recurrentHCVwere treated with sofosbuvir either in combination with simeprevir, or in combination with ribavirin or daclatasvir with or without ribavirin for 12 weeks. Biochemical parameters, tacrolimus trough levels, and the maximal liver function capacity (LiMAx) were measured monthly during the treatment and 12 weeks after the end of treatment.Results: All patients achieved sustained virological response 12 weeks after the end of the treatment. The transaminases and cholestasis parameters normalized until week 8 of treatment. The mean LiMAx (normal ranges >315 μg/kg/h) increased from 344±142 μg/kg/h before treatment to 458±170 μg/kg/h (P<.0001) at the 12‐week follow‐up. In parallel, the tacrolimus trough level to dose ratio decreased from 4.68 down to 2.72 (P=.0004).Conclusion: Antiviral treatment withDAAs enabled sustained elimination of recurrentHCVin liver transplant recipients and was associated with a significant improvement of the enzymatic liver function.Keywords
Funding Information
- Charité Universitätsmedizin Berlin
This publication has 29 references indexed in Scilit:
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipientsTransplant International, 2012
- Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post‐transplant weekClinical Transplantation, 2011
- How to define initial poor graft function after liver transplantation? - a new functional definition by the LiMAx testTransplant International, 2010
- Prediction of Postoperative Outcome After Hepatectomy With a New Bedside Test for Maximal Liver Function CapacityAnnals of Surgery, 2009
- Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirinJournal of Hepatology, 2008
- Fibrosis Progression in Hepatitis C Positive Liver Recipients After Sustained Virologic Response to Antiviral Combination Therapy (Interferon???Ribavirin Therapy)Transplantation, 2007
- Interferon-Based Combination Anti-Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative AnalysisAmerican Journal of Transplantation, 2006
- Cytochrome P450 3A polymorphisms and immunosuppressive drugsPharmacogenomics, 2005
- Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejectionLiver Transplantation, 2003